Thong Huy Cao

Dr. Thong Huy Cao

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in JACC
Verified
Journal Article
Closed access
LNLeong L. Ng
Leong L. Ng
ISIain B. Squire
Iain B. Squire
DJDonald J.L. Jones
Donald J.L. Jones
TCThong Huy Cao
Thong Huy Cao
DCDaniel C.S. Chan
Daniel C.S. Chan
CMChristian Mueller
Christian Mueller

6 November 2019 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
TCThong Huy Cao
Thong Huy Cao
DJDonald J.L. Jones
Donald J.L. Jones
AVAdriaan A. Voors
Adriaan A. Voors
PQPaulene A. Quinn
Paulene A. Quinn
JSJatinderpal K. Sandhu
Jatinderpal K. Sandhu
LNLeong L. Ng
Leong L. Ng
Aims: To provide insights into pathogenesis of disease progression and potential novel treatment targets for patients with heart failure by investigation of the plasma proteome using network analysis. Methods and results: The plasma proteome of 50 patients with heart failure who died or were rehospitalised were compared with 50 patients with heart failure, matched for age and sex, who did not have an event. Peptides were analysed on two-dimensional liquid chromatography coupled to tandem mass spectrometry (2D LC ESI-MS/MS) in high definition mode (HDMSE). We identified and quantified 3001 proteins, of which 51 were significantly up-regulated and 46 down-regulated with more than two-fold expression changes in those who experienced death or rehospitalisation. Gene ontology enrichment analysis and protein–protein interaction networks of significant differentially expressed proteins discovered the central role of metabolic processes in clinical outcomes of patients with heart failure. The findings revealed that a cluster of proteins related to glutathione metabolism, arginine and proline metabolism, and pyruvate metabolism in the pathogenesis of poor outcome in patients with heart failure who died or were rehospitalised. Conclusions: Our findings show that in patients with heart failure who died or were rehospitalised, the glutathione, arginine and proline, and pyruvate pathways were activated. These pathways might be potential targets for therapies to improve poor outcomes in patients with heart failure.

18 December 2017 in European Journal of Heart Failure
Verified
Journal Article
Closed access
PDF file
JEJohanna Elisabeth Emmens
Johanna Elisabeth Emmens
DJDonald J.L. Jones
Donald J.L. Jones
TCThong Huy Cao
Thong Huy Cao
DCDaniel C.S. Chan
Daniel C.S. Chan
SRSimon P.R. Romaine
Simon P.R. Romaine
LNLeong L. Ng
Leong L. Ng

1 February 2015 in The Lancet
Verified
Journal Article
Closed access
TCThong Huy Cao
Thong Huy Cao
PQPaulene A Quinn
Paulene A Quinn
JSJatinderpal K Sandhu
Jatinderpal K Sandhu
AVAdriaan A Voors
Adriaan A Voors
CLChim C. Lang
Chim C. Lang
LNLeong Loke Ng
Leong Loke Ng

14 February 2019 in Clinical Research in Cardiology
Verified
Journal Article
Open access
PDF file
ONOn behalf of the GREAT (Global REsearch on Acute Conditions Team) Network
On behalf of the GREAT (Global REsearch on Acute Conditions Team) Network
PKPrathap Kanagala
Prathap Kanagala
ISIain B. Squire
Iain B. Squire
DJDonald J. L. Jones
Donald J. L. Jones
TCThong Huy Cao
Thong Huy Cao
LNLeong L. Ng
Leong L. Ng
Background Proenkephalin (PENK), a stable endogenous opioid biomarker related to renal function, has prognostic utility in acute and chronic heart failure. We investigated the prognostic utility of PENK in heart failure with preserved ejection fraction (HFpEF), and its relationship to renal function, Body Mass Index (BMI), and imaging measures of diastolic dysfunction. Methods In this multicentre study, PENK was measured in 522 HFpEF patients (ejection fraction > 50%, 253 male, mean age 76.13 ± 10.73 years) and compared to 47 age and sex-matched controls. The primary endpoint was 2-years composite of all-cause mortality and/or heart failure rehospitalisation (HF). A subset (n = 163) received detailed imaging studies. Results PENK levels were raised in HFpEF (median [interquartile range] 88.9 [62.1–132.0]) compared to normal controls (56.3 [47.9–70.5]). PENK was correlated to urea, eGFR, Body Mass Index and E/e′ (rs 0.635, − 0.741, − 0.275, 0.476, respectively, p < 0.0005). During 2 years follow-up 144 patients died and 220 had death/HF endpoints. Multivariable Cox regression models showed PENK independently predicted 2 year death/HF [hazard ratio (for 1 SD increment of log-transformed biomarker) HR 1.45 [95% CI 1.12–1.88, p = 0.005]], even after adjustment for troponin (HR 1.59 [1.14–2.20, p = 0.006]), and Body Mass Index (HR 1.63 [1.13–2.33, p = 0.009]). PENK showed no interaction with ejection fraction status for prediction of poor outcomes. Net reclassification analyses showed PENK significantly improved classification of death/HF outcomes for multivariable models containing natriuretic peptide, troponin and Body Mass Index (p < 0.05 for all). Conclusions In HFpEF, PENK levels are related to BMI, and measures of diastolic dysfunction and are prognostic for all-cause mortality and heart failure rehospitalisation.

9 August 2024 in European Journal of Heart Failure
Verified
Journal Article
Open access
TCThong Huy Cao
Thong Huy Cao
WTWan Ting Tay
Wan Ting Tay
DJDonald J.L. Jones
Donald J.L. Jones
JCJohn George Franklin Cleland
John George Franklin Cleland
JTJasper Tromp
Jasper Tromp
LNLeong L. Ng
Leong L. Ng
Aims: We investigated the prevalence, clinical characteristics, and prognosis of patients with heart failure (HF) with improved ejection fraction (HFimpEF). Methods and results: We used data from BIOSTAT‐CHF including patients with a left ventricular ejection fraction (LVEF) ≤40% at baseline who had LVEF re‐assessed at 9 months. HFimpEF was defined as a LVEF >40% and a LVEF ≥10% increase from baseline at 9 months. We validated findings in the ASIAN‐HF registry. The primary outcome was a composite of time to HF rehospitalization or all‐cause mortality. In BIOSTAT‐CHF, about 20% of patients developed HFimpEF, that was associated with a lower primary event rate of all‐cause mortality (hazard ratio [HR] 0.52, 95% confidence interval [CI] 0.28–0.97, p = 0.040) and the composite endpoint (HR 0.46, 95% CI 0.30–0.70, p < 0.001) compared with patients who remained in persistent HF with reduced ejection fraction (HFrEF). The findings were similar in the ASIAN‐HF (HR 0.40, 95% CI 0.18–0.89, p = 0.024, and HR 0.29, 95% CI 0.17–0.48, p < 0.001). Five independently common predictors for HFimpEF in both BIOSTAT‐CHF and ASIAN‐HF were female sex, absence of ischaemic heart disease, higher LVEF, smaller left ventricular end‐diastolic and end‐systolic diameter at baseline. A predictive model combining only five predictors (absence of ischaemic heart disease and left bundle branch block, smaller left ventricular end‐systolic and left atrial diameter, and higher platelet count) for HFimpEF in the BIOSTAT‐CHF achieved an area under the curve of 0.772 and 0.688 in the ASIAN‐HF (due to missing left atrial diameter and platelet count). Conclusions: Approximately 20–30% of patients with HFrEF improved to HFimpEF within 1 year with better clinical outcomes. In addition, the predictive model with clinical predictors could more accurately predict HFimpEF in patients with HFrEF.